Izertis, S.A. ("**Izertis**" or the "**Company**"), pursuant to Article 226 of the Spanish Securities Market Act (*Ley 6/2023, de 17 de marzo, de los Mercados de Capitales y de los Servicios de Inversión*), hereby discloses the following

INSIDE INFORMATION (*INFORMACIÓN PRIVILEGIADA*)

The Company has resolved, pursuant to the authorization granted by the General Shareholders' Meeting held on 27 June 2025, under item six of the agenda, to carry out a share capital increase by means of cash contributions and with exclusion of pre-emptive subscription rights, for an effective amount (nominal plus premium) of, approximately, €51.3 million (the "**Capital Increase**"), by means of the issuance up to a maximum of 5,576,141 new ordinary shares, with a nominal value of €0.10 per share, of the same class and series as the currently outstanding shares, representing 19.21% of the current share capital. (the "**New Shares**"). The New Shares will grant their holders the same rights as the share of Izertis currently outstanding from their registration in the accounting records of the *Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U*.

Furthermore, it is reported that the Company has agreed to sell up to a maximum of 304,749 shares from its treasury stock (the "**Treasury Shares**"), representing 1.05% of the current share capital, subject to the same terms and conditions established for the Capital Increase. The sell of Treasury Shares, together with the Capital Increase, the "**Placement**".

Therefore, the effective amount (nominal plus premium) of the Placement is expected to be approximately €54.1 million.

The Placement will be conducted through a private placement by means of an accelerated book-building process exclusively directed to qualified investors.

In the context of the Placement, the Company has received indications of interest from anchor investors, including the Italian asset management firm Alkemia Capital, at a price of €9.2 per share, for an aggregate amount of approximately €39.3 million.

The main terms and conditions of the Placement are the following:

1. RATIONALE

The main rationale of the Placement is to finance the Company's growth, both organic and inorganic, within the framework of its strategic plan.

2. PLACEMENT PRICE

The placement price of the New Shares and the Treasury Shares will be determined through a demand prospecting process carried out as part of an accelerated bookbuild offering exclusively among qualified investors (see section 3 below). In this regard, the placement price of the New Shares and the Treasury Shares will correspond to the nominal value of the Company's outstanding shares (€0.10) plus the issuance premium determined based on the demand survey carried out as part of the accelerated bookbuild offering.

3. ADDRESSEES OF THE PLACEMENT

The Placement will be solely addressed to qualified investors, as defined, (i) in the European Union, as defined in Article 2 (e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC (the "**Prospectus Regulation**"); and (ii) in other countries, in a manner such as that investors may have such condition or equivalent category, in accordance with each jurisdiction's applicable law so that according with such law, the Placement does not require to be registered with or approved by any competent authority. The New Shares and the Treasury Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), or with any securities regulatory authority of any state or other jurisdiction of the United States. The New Shares and the Treasury Shares may only be offered, sold or otherwise transferred in offshore transactions outside the United States as defined in, and in reliance on, Regulation S under the Securities Act. Under no circumstances will any direct selling efforts be made in the United States of America in connection with the New Shares and the Treasury Shares.

4. DESCRIPTION OF THE PLACEMENT

The Company has entered on 28 January 2026 into a placing agreement with JB Capital Markets, S.V., S.A.U., as coordinator and placement entity, and Alantra Equities, S.V., S.A., as placement entity (jointly, the "**Managers**").

Following the publication of this inside information (*información privilegiada*), the Managers will conduct an accelerated bookbuild offering among qualified investors, which is expected to finalize no later than 29 January 2026 at 8:00 a.m., during which they will act with due care to procure subscribers for the New Shares and the Treasury Shares.

Additionally, the Company has entered on 28 January 2026 into an agency agreement with Renta 4 Banco, S.A.

On the other hand, Ramón y Cajal Abogados, S.L.P. acts as legal advisor to the Company and Gómez-Acebo & Pombo Abogados, S.L.P. acts as legal advisor to the Managers.

5. RESULT OF THE PLACEMENT

Once the private placement process is finalized, the Company will communicate the results by means of the publication of an inside information announcement (*información privilegiada*) on the website of the Spanish Securities Market Commission (*Comisión Nacional del Mercado de Valores*) ("**CNMV**"), including, among others, the final number of New Shares to be issued and the Treasury Shares sold, as well as their placement price.

6. APPLICATION FOR ADMISSION TO TRADING

The Company will apply for admission of the New Shares to listing on the Stock Exchanges of Madrid, Barcelona, Bilbao and Valencia and to trading on the Automated Quotation System (*Sistema de Interconexión Bursátil*), with no need for registration and approval by the CNMV of a prospectus in accordance with Articles 1.4 (a) and 1.5 (a) of the Prospectus Regulation.

izertis

7. REPORT

In accordance with the provisions of the Spanish Companies Act (*texto refundido de la Ley de Sociedades de Capital aprobado por el Real Decreto Legislativo 1/2010, de 2 de julio*), regarding the resolution to the Capital Increase, the Board of Directors has drawn up the corresponding directors' report. Such report will be made available to the shareholders of Izertis in the manner prescribed by applicable regulations.

8. LOCK-UP

The Company has agreed to a lock-up commitment on customary terms during a period of 90 days from the date of the placing agreement, subject to customary exceptions in this type of transactions.

In Gijón, on 28 January 2026.

The previous English translation is provided by the Company for information purposes only, based on the original and official document in Spanish available on the Company's website (www.izertis.com). In the event of any discrepancy between the English version and the Spanish original document, the latter shall prevail.